Bioxytran (BIXT) 10-Q2019 Q1 Quarterly report

Filed: 10 May 19, 2:46pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: accretion, activity, Additionally, Advisor, aggregate, average, bank, barrier, bid, Black, blood, bring, cell, chose, commit, commitment, comparison, component, computed, contractual, conventional, crossing, curtail, de, delay, diffuse, dilution, discount, discounted, discretion, Distinguishing, equal, equivalent, exclusive, exercisable, exercise, expiration, factor, failure, FDA, feature, Flat, Food, forced, foreign, forty, free, injectable, injected, instrument, insufficiency, intellectual, intercompany, interfering, intravenously, investor, IR, ischemic, Juan, lender, lesser, level, license, life, linked, long, Lopez, lowest, maturing, Maturity, MDX, membrane, mentor, notice, NW, objectivity, ote, patent, person, pick, premium, prepay, prepayment, Probe, problem, property, prorated, protection, protective, red, redemption, registered, repay, repurchase, RU, stay, strategic, submission, successor, Talavera, terminated, termination, thereof, thousand, tranche, travel, treat, twenty, unamortized, undiscounted, Unlimited, variable, vi, Viewer, volatility, volume, warrant, weighted, wound

Removed: acquisition, agriculture, animal, annually, appointed, audit, broad, CEO, CFO, Chairman, charge, commercial, committee, comprised, contemplate, converted, earth, evaluate, experience, expert, forward, full, improvement, incorporated, increasing, independent, internationally, made, multiple, November, NYSE, obtained, oversight, paragraph, posted, production, qualified, rare, recently, requiring, served, site, submitted, supply, vote

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

BIXT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of BIOXYTRAN, Inc. (the “Company”) for the quarter ending March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), David Platt, Chief Executive Officer and Ola Soderquist, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:

(1)

The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 10, 2019	By:	/s/ David Platt
		David Platt
		Chief Executive Officer

		/s/ Ola Soderquist
		Ola Soderquist
		Chief Financial Officer